1,721,407 research outputs found
Comunicare il trasferimento tecnologico. Un confronto qualitativo tra l’ENEA e Centri di Ricerca nazionali ed internazionali
No full textTriple combinations in chronic obstructive pulmonary disease – is three better than two?
No full text
Advanced interaction paradigms to define smart visit experiences in the internet of things era
No full textThe growing spread of smart objects is changing the way humans interact with technologies since the interaction they propose is more and more physical and less virtual. From an HCI perspective, one of the most interesting aspects regards how non-technical end users can program the behavior of such smart objects. This poster presents an ongoing project on three novel interaction paradigms that support the creation of smart visit experiences. Copyright is held by the author/owner(s)
An Obvious Paradigm: Choosing Bronchodilators and Inhaled Corticosteroids for Their Pharmacologic Characteristics
No full textBronchodilators: current and future
No full textBronchodilators are central in the symptomatic treatment of chronic obstructive pulmonary disease (COPD), although there is often limited reversibility of airflow obstruction. Three classes of bronchodilators (β2-agonists, antimuscarinic agents, methylxanthines) are currently available, which can be used individually, or in combination with each other or inhaled corticosteroids. Novel classes of bronchodilators have proved difficult to develop. The muscarinic β2-agonist molecules approach likely provides the best opportunity to develop combinations that combine corticosteroids with dual-bronchodilator activities, and thus potentially achieve better efficacy than is apparent with the current combination products that dominate the treatment of COPD
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
Full text linkAn increasing body of evidence suggests that the long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) combination appears to play an important role in maximizing bronchodilation, with studies to date indicating that combining different classes of bronchodilators may result in significantly greater improvements in lung function compared to the use of a single drug, and that these combinations are well tolerated in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). An inhaled, fixed-dose combination of two 24-hour bronchodilators, the LAMA umeclidinium and the LABA vilanterol, is under development as a once-daily treatment for COPD. The efficacy of both mono-components has already been demonstrated. The information currently available suggests that umeclidinium/vilanterol is an effective once-daily dual bronchodilator fixed-dose combination in the treatment of COPD. However, it remains to be seen if it compares favorably with current therapies. Moreover, the question remains whether umeclidinium/vilanterol fixed-dose combination, which significantly improves FEV1, is also associated with improvements in other outcome measures that are important to COPD patients
- …
